Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
← catalyst calendarNCT06819007 · readout in 805 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
582estimated
Sites
208
Countries
Australia, Austria, Belgium +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-19 | actual | When the study began enrolling |
| Primary completion | 2028-11-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ovarian Cancer
Interventions
- Drug: Trastuzumab Deruxtecan — also filed as T-DXd, ENHERTU®
- Drug: Bevacizumab
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ population
measured From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed